CTLA4 and head and neck squamous cell carcinoma: Here, we present the results of the phase II part of the MOVIE trial in which the antitumor activity and safety of oral metronomic vinorelbine combined with dual anti-PD-L1 durvalumab and anti-CTLA-4 tremelimumab immunotherapy were assessed in pretreated advanced HNSCC patients.